PharmaCyte Biotech shares surge 56.78% after-hours on FDA approval optimism and Femasys stake monetization boosting cash reserves.

PharmaCyte Biotech surged 56.78% in after-hours trading, driven by FDA-related optimism and the successful monetization of its stake in Femasys Inc., which boosted cash reserves to $20 million. Recent news highlighted the company’s strategic capital deployment, with a 50% intraday rally earlier in the day attributed to speculative interest in cancer therapy advancements and improved liquidity. The stock’s sharp after-hours gain reflects sustained momentum from these catalysts, despite underlying financial challenges such as a $8.36 million net loss. The FDA approval narrative and strengthened cash position appear to have amplified investor enthusiasm, aligning with the biotech sector’s volatile nature and risk-on sentiment.